VISEN Pharma Repurchases 4,700 Shares, Expanding Treasury Stock to 153,100

Bulletin Express06-17

VISEN Pharmaceuticals (VISEN Pharma), a Cayman Islands-incorporated biotech firm listed in Hong Kong, disclosed a minor on-market share repurchase executed on 17 June 2026.

The company bought back 4,700 ordinary shares at prices between HKD 19.35 and HKD 19.67, for a total consideration of HKD 0.09 million. The volume-weighted average price was approximately HKD 19.42 per share.

Key post-transaction metrics: • Issued shares outstanding (excluding treasury shares) decreased to 113.77 million, representing a 0.004 % reduction from the preceding day’s balance. • Treasury shares rose to 153,100, keeping the total issued share count steady at 113.93 million. • Cumulative buybacks under the repurchase mandate approved on 27 June 2025 now stand at 153,100 shares, equivalent to 0.13 % of the 113.93 million shares authorized for repurchase (11.39 million). • In line with Hong Kong listing rules, VISEN Pharma is subject to a moratorium on new share issues or treasury-share sales until 17 July 2026.

The board confirms that the repurchase complied with all applicable listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161646566?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161646566","market":"us","top_or_hot":-1,"title":"VISEN Pharma Repurchases 4,700 Shares, Expanding Treasury Stock to 153,100","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals (VISEN Pharma), a Cayman Islands-incorporated biotech firm listed in Hong Kong, disclosed a minor on-market share repurchase executed on 17 June 2026.</p>\n<p>The company bought back 4,700 ordinary shares at prices between HKD 19.35 and HKD 19.67, for a total consideration of HKD 0.09 million. The volume-weighted average price was approximately HKD 19.42 per share.</p>\n<p>Key post-transaction metrics:\n• Issued shares outstanding (excluding treasury shares) decreased to 113.77 million, representing a 0.004 % reduction from the preceding day’s balance.  \n• Treasury shares rose to 153,100, keeping the total issued share count steady at 113.93 million.  \n• Cumulative buybacks under the repurchase mandate approved on 27 June 2025 now stand at 153,100 shares, equivalent to 0.13 % of the 113.93 million shares authorized for repurchase (11.39 million).  \n• In line with Hong Kong listing rules, VISEN Pharma is subject to a moratorium on new share issues or treasury-share sales until 17 July 2026.</p>\n<p>The board confirms that the repurchase complied with all applicable listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharma Repurchases 4,700 Shares, Expanding Treasury Stock to 153,100</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharma Repurchases 4,700 Shares, Expanding Treasury Stock to 153,100\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-17 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals (VISEN Pharma), a Cayman Islands-incorporated biotech firm listed in Hong Kong, disclosed a minor on-market share repurchase executed on 17 June 2026.</p>\n<p>The company bought back 4,700 ordinary shares at prices between HKD 19.35 and HKD 19.67, for a total consideration of HKD 0.09 million. The volume-weighted average price was approximately HKD 19.42 per share.</p>\n<p>Key post-transaction metrics:\n• Issued shares outstanding (excluding treasury shares) decreased to 113.77 million, representing a 0.004 % reduction from the preceding day’s balance.  \n• Treasury shares rose to 153,100, keeping the total issued share count steady at 113.93 million.  \n• Cumulative buybacks under the repurchase mandate approved on 27 June 2025 now stand at 153,100 shares, equivalent to 0.13 % of the 113.93 million shares authorized for repurchase (11.39 million).  \n• In line with Hong Kong listing rules, VISEN Pharma is subject to a moratorium on new share issues or treasury-share sales until 17 July 2026.</p>\n<p>The board confirms that the repurchase complied with all applicable listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1161646566","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161646566","pubTimestamp":1781695572,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals (VISEN Pharma), a Cayman Islands-incorporated biotech firm listed in Hong Kong, disclosed a minor on-market share repurchase executed on 17 June 2026. The company bought back...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"VISEN Pharma回购4,700股，库存股扩大至153,100股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals (VISEN Pharma), a Cayman Islands-incorporated biotech firm listed in Hong Kong, disclosed a minor on-market share repurchase executed on 17 June 2026.\nThe company bought back 4,700 ordinary shares at prices between HKD 19.35 and HKD 19.67, for a total consideration of HKD 0.09 million. The volume-weighted average price was approximately HKD 19.42 per share.\nKey post-transaction metrics:\n• Issued shares outstanding (excluding treasury shares) decreased to 113.77 million, representing a 0.004 % reduction from the preceding day’s balance.  \n• Treasury shares rose to 153,100, keeping the total issued share count steady at 113.93 million.  \n• Cumulative buybacks under the repurchase mandate approved on 27 June 2025 now stand at 153,100 shares, equivalent to 0.13 % of the 113.93 million shares authorized for repurchase (11.39 million).  \n• In line with Hong Kong listing rules, VISEN Pharma is subject to a moratorium on new share issues or treasury-share sales until 17 July 2026.\nThe board confirms that the repurchase complied with all applicable listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161646566","isCrawlerRequest":true}